Heartbeam

BEAT

Market cap $76.5M

HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.

HeartBeam, Inc.'s (NASDAQ: BEAT) stock is trading higher on Monday, with a session volume of 193.38 million compared to the average volume of 2.191 million as per data from Benzinga Pro.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application.

HeartBeam, Inc. ( BEAT ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Robert Eno - CEO, Chief Business Officer & Director Timothy Cruickshank - Chief Financial Officer Conference Call Participants Kyle Bauser - ROTH Capital Partners, LLC, Research Division William Sutherland - The Benchmark Company, LLC, Research Division Presentation Operator Greetings, and welcome to the HeartBeam Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2025 Results.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam's Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Participate at Upcoming Industry and Investor Conferences, September 4-10, 2025.